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ABSTRACT 
 
Very long chain acyl-CoA dehydrogenase deficiency is an autosomal recessive 
genetic disorder in which the first step in the mitochondrial β-oxidation of 
fatty acids for 14-20 carbons is defective. Clinical presentation is 
heterogeneous ranging from the severe neonatal form presenting with hypo-
ketotic hypoglycemia, liver dysfunction and rapidly fatal cardiomyopathy with 
episodes of hypo-ketotic hypoglycemia in infants. Herein we report a patient 
with novel homozygous missense mutation c.1391C>A in exon 14 with a 
severe neonatal onset type who presented with hypoketotic hypoglycemia, 
cardiomyopathy and hepatomegaly. 
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ÖZET 
 
Çok uzun zincirli açil-KoAdehidrogenaz eksikliği, yağ asitlerinin mitokondriyal 
beta-oksidasyonunda ilk basamak olan 14-20 karbonlu yağ asit 
oksidasyonunun defektif olduğu otozomal resesif geçiş gösteren genetik bir 
hastalıktır. Klinik başvuru şekli hipoketotik hipoglisemi, karaciğer yetmezliği ve 
hızlı seyirli fatal kardiyomyopatinin eşlik ettiği form ile hafif hipoketotik 
hipoliseminin eşlik ettiği infant form arasında heterojendir. Burada, 
hipoketotik hipoglisemi, hepatomegali ve kardiyomyopati ile başvuran, exon 
14’de c.1391C>A yeni tanımlanmış homozigot missense mutasyon saptanan, 
ciddi yenidoğan başlangıçlı bir çok uzun zincirli açil-KoA eksikliği vakası 
sunulmaktadır.  
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INTRODUCTION 
 
Very long chain acyl-CoA dehydrogenase deficiency (VLCADD) was first 
described in 1993. It is an autosomal recessive genetic disorder in which the 
first step in the mitochondrial β-oxidation spiral of fatty acids for 14-20 
carbons is defective (1). The phenotype is heterogeneous ranging from 
thesevere neonatal form presenting with hypo-ketotic hypoglycemia, liver 
dysfunction and rapidly fatal cardiomyopathy overthe infantile formwith 
episodes of hypo-ketotic hypoglycemia and liver dysfunction to the adult 
myopathicform (2).VLCADD is implemented in newborn screening in the US 
and several European countries (3). In view of the emerging genotype-
phenotype correlation in this disorder genetic confirmation may be helpful in 
designing the appropriate therapeutic regime for these patients. Here we 
report a patient with novel homozygous missense mutationc.1391C>A in exon 
14with a severe neonatal onset type who presented 
withhypoketotichypoglycemia, cardiomyopathy and hepatomegaly. 
 
 
 
 
 
 
CASE REPORT 
 
The patient was bornat 40 weeks of gestation by spontaneous delivery 
afteran uncomplicated pregnancyas fourth child from consanguineous 
parents. There was one sibling with SIDS at 3 months of age. Apart from a 
single hypoglycemia atthe first day of life our patient had an uncomplicated 
neonatal adaptationand was discharged home at three days. At age 4 months, 
he presented with vomiting and diarrhea to a local emergency and had to be 
admitted to the pediatric ICU because of dehydration, metabolic acidosis, and 
hypoglycemia. Physical examination revealed tachycardia, hepatomegaly and 
muscular hypotonia. The liver was 7 cm below the right costal margin. 
Abdominal ultrasonography confirmed thehepatomegaly and revealed a 
steatosis. Echocardiography showed left ventricular hypertrophy. 
 
 
 
323 Case Report / Olgu Sunumu 
 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
69
15
 
| 
do
wn
lo
ad
ed
: 
27
.1
.2
02
0
  
 
 
Laboratory investigations revealed elevated creatine kinase level of 1844 U/L 
(normal range, 60-305 U/L) and a borderline blood glucose level of 2.38 
mmol/l (43 mg/dl) with negativeurine ketone, lactate 11.1mmol/l (100 mg/dl), 
uric acid level of 482umol/l (8.1 mg/dl), AST level of 162 U/L and ALT level of 
91 U/L and triglyceride level of 818 mg/dl. Plasma acylcarnitine profile 
demonstrated elevations in multiple long chain acylcarnitine species (C14:1 
level of 1.25 µmol/L (normal value <0.6), C14 level of  1.68 µmol/L (nv<0.8), 
C14: 2 level of 0.28 µmol/L (<0.18), C16:1 level of 1.32 µmol/L (nv: <1.04), 
C18:1 3.86 µmol/L (nv: <3.53)free carnitine level was low 2.25 µmol/L (nv:3.8-
50 µmol/L). Organic acid profile showed marked dicarboxlicaciduria indicating 
VLCADD. DNA sequencing of ACADVL, revealed a yet unreported homozygous 
missense mutation (c.1391C>A) in exon 14. Family studies confirmed the 
disease causing mutation. The treatment with a medium chain triglyceride-
rich diet and frequent feeding was started. However the patient died 
unexpectedly one month after the diagnosis, supposedly fromcardiac 
dysrhythmia secondary to hypertrophy in left ventricle.  
 
DISCUSSION 
 
VLCADD is an autosomal recessive disorder of fatty acid oxidation. VLCAD 
catalyzes the initial step of mitochondrial β-oxidation of long chain fatty acids 
with a chain length of 14 to 18 carbons. Heart, liver, and skeletal muscle, all 
requiring high amounts of ATP, are the most affected organs (1,2). Early 
diagnosis and treatment is essential to prevent cardiomyopathy, arrhythmia, 
hypoketotic hypoglycemia, rhabdomyolysis and death. Neonatal screening 
programs for VLCADD have been implemented recently in various countries 
(3). Mildly elevated C14:1 carnitine on third day of newborn strongly suggests 
VLCADD. Patients with VLCADD detected thorough newborn screening are 
usually asymptomatic during the well state but they are at risk for metabolic 
decompensation during catabolic episodes such as intercurrent infections or 
other episodes of fasting (2,3).Genetic an enzymatic confirmation is of 
importance due to the wide variety of clinical presentations ranging from 
severe neonatal to mild adult myopathic variants. Implementation of newborn 
screening usually leads to an increasing incidence of VLCADD due a great 
number of asymptomatic patients with a good outcome after timely diagnosis 
(4-7). But overall the severe neonatal form is the most common type and 
presents with cardiomyopathy and hepatopathy and has the highest mortality 
thus justifying neonatal screening.The presentation of our patient with 
hypoketotic hypoglycemia, acute liver steatosis with 
hepatomegaly,cardiomyopathy, and rhabdomyolysis and the  history of 
unexplained death of a sibling were very suggestive a beta oxidation disorder 
(7-10). In countries where newborn screening is not available for these 
disorders, diagnosiscan be reached with acylcarnitine, organic acid analysis 
and VLCAD enzymatic analysis (10-11).In view of the emerging genotype-
phenotype correlation in this disorder, with low residual activity-associated 
deletions and nonsense mutations and variable disease-associated missense 
mutations. Genetic confirmation and enzymatic analysis is helpful in designing 
the appropriate follow-up and therapeutic regime for these patients. The 
mainstay of therapy is the prevention of recurrent attacks by an anti-catabolic 
therapy during surgery, prolonged fasting, perioperative stress to minimize 
fasting stress (12-13).  
In summary we present a new missense mutation(c.1391C>A)associated 
with a severe neonatal VLCADD phenotype. 
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